| Dr Miranda E Saylor, AUD | |
|
1133 College Ave Ste A101, Manhattan, KS 66502-2795 | |
| (785) 539-7361 | |
| (785) 539-8529 |
| Full Name | Dr Miranda E Saylor |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 1133 College Ave Ste A101, Manhattan, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891421251 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 2443 (Kansas) | Primary |
| Provider Name | Associated Audiologists Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1225191315 PECOS PAC ID: 4183693187 Enrollment ID: O20040927000974 |
News Archive
Are you ready to quit smoking and willing to share the good, bad, and ugly about your experience If so, the National Cancer Institute (NCI) wants to feature you on their Smokefree Women Web site as part of the Women Who Quit campaign.
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
In advance of International Women's Day on 8 March 2014, WHO is launching new guidance to help countries ensure human rights are respected in providing more girls, women, and couples with the information and services they need to avoid unwanted pregnancies.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
A new study published in The Lancet Diabetes & Endocrinology reveals a sophisticated new model showing how excessive calorie intake affects the weight of children and adolescents, which could lead to improved weight loss interventions for obese and overweight children.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Miranda E Saylor, AUD Po Box 19087, Lenexa, KS 66285-9087 Ph: (913) 262-5855 | Dr Miranda E Saylor, AUD 1133 College Ave Ste A101, Manhattan, KS 66502-2795 Ph: (785) 539-7361 |
News Archive
Are you ready to quit smoking and willing to share the good, bad, and ugly about your experience If so, the National Cancer Institute (NCI) wants to feature you on their Smokefree Women Web site as part of the Women Who Quit campaign.
For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.
In advance of International Women's Day on 8 March 2014, WHO is launching new guidance to help countries ensure human rights are respected in providing more girls, women, and couples with the information and services they need to avoid unwanted pregnancies.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Novartis' breast cancer treatment Femara® (letrozole) Tablets, 2.5 mg. Final approval of Teva's Letrozole Tablets is expected upon expiry of patent protection for the brand product in June 2011.
A new study published in The Lancet Diabetes & Endocrinology reveals a sophisticated new model showing how excessive calorie intake affects the weight of children and adolescents, which could lead to improved weight loss interventions for obese and overweight children.
› Verified 2 days ago
Dr. Melizabeth Ritchie Maatta, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1133 College Ave, Suite 101a, Manhattan, KS 66502 Phone: 785-776-7534 | |
Dr. Jason Michael Harader, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: 4201 Anderson Avenue, Bldg. C, Manhattan, KS 66503 Phone: 785-539-3504 Fax: 785-539-7430 | |
Dr. Kevin P Ruggle, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 1213 Hylton Heights Rd, Ste 105, Manhattan, KS 66502 Phone: 785-537-4005 | |
Advanced Audiology Inc Audiologist Medicare: Medicare Enrolled Practice Location: 1133 College Ave, Suite C145, Manhattan, KS 66502 Phone: 785-320-7388 Fax: 785-320-6056 | |
Audiology Associates, Inc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1133 College Ave, Suite 101a, Manhattan, KS 66502 Phone: 785-539-7361 | |
Dr. Charles L Gillum, AUD. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1213 Hylton Heights Rd, Sutie 105, Manhattan, KS 66502 Phone: 785-537-4005 | |
Audiology Center Inc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1213 Hylton Heights Rd, Suite 105, Manhattan, KS 66502 Phone: 785-537-4005 |